Compare Estee Lauder Companies Inc (EL) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Enveric Biosciences Inc — how do they compare? Estee Lauder Companies Inc trades at $82.49 (market cap $29.78B), while Enveric Biosciences Inc trades at $1.37 (market cap $5.32M). The key difference: Estee Lauder Companies Inc is far larger — about 5597.7× Enveric Biosciences Inc's market cap, and Estee Lauder Companies Inc pays a 1.7% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| EL | ENVB | |
|---|---|---|
Market Cap | $29.78B | $5.32M |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $17.40 |
52-Week Low | $67.23 | $1.28 |
Enterprise Value | $35.95B | $408.82K |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $82.72, up 2.3% with recent earnings beats but faces fundamental challenges including a negative net income margin of -1.67% and elevated P/E ratio of 147.8. Technical indicators show bearish momentum with support at $81 and resistance at $84. The company maintains strong gross margins at 74.71% and positive analyst sentiment with 44% buy ratings and $90.60 consensus target.
While recent earnings outperformance and strong brand positioning provide upside potential, investors face risks from declining revenue trends, negative profitability, and high valuation multiples. The stock's near-term direction will depend on Q2 2026 earnings delivery and management's ability to restore sustainable growth amid competitive pressures.
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
